



## (51) International Patent Classification:

**A61K 31/337** (2006.01)    **A61K 31/513** (2006.01)  
**A61K 31/475** (2006.01)    **A61K 31/555** (2006.01)  
**A61K 31/519** (2006.01)    **A61K 31/704** (2006.01)  
**A61K 38/18** (2006.01)    **A61K 31/7048** (2006.01)  
**A61K 45/06** (2006.01)    **A61K 33/24** (2006.01)  
**A61P 35/00** (2006.01)    **A61K 38/17** (2006.01)  
**A61K 39/395** (2006.01)    **C07K 19/00** (2006.01)  
**A61K 31/4745** (2006.01)

## (21) International Application Number:

PCT/US2011/060666

## (22) International Filing Date:

14 November 2011 (14.11.2011)

## (25) Filing Language:

English

## (26) Publication Language:

English

## (30) Priority Data:

61/413,940    15 November 2010 (15.11.2010)    US  
 61/421,462    9 December 2010 (09.12.2010)    US

(71) Applicant (for all designated States except US): **FIVE PRIME THERAPEUTICS, INC.** [US/US]; Two Corporate Drive, South San Francisco, California 94080 (US).

## (72) Inventors; and

(75) Inventors/Applicants (for US only): **LONG, Li** [CA/US]; 3209 Greenhills Drive, Lafayette, California 94549 (US). **BRENNAN, Thomas** [US/US]; 5294 Amelia Drive, San Jose, California 95118 (US).

(74) Agent: **FORDIS, Jean B.**; Finnegan, Henderson, Farabow, Garrett & Dunner LLP, 901 New York Avenue, NW, Washington, DC 20001-4413 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

## Published:

— with international search report (Art. 21(3))  
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))  
 — with sequence listing part of description (Rule 5.2(a))

## (54) Title: FGFR1 EXTRACELLULAR DOMAIN COMBINATION THERAPIES




FIGURE 1

(57) Abstract: Methods of treating cancer comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule in combination with at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are provided. Dosage packs comprising an FGFR1 ECD and/or an FGFR1 ECD fusion molecule and/or at least one additional therapeutic agent selected from docetaxel, paclitaxel, vincristine, carboplatin, cisplatin, oxaliplatin, doxorubicin, 5-fluorouracil (5-FU), leucovorin, pemetrexed, and bevacizumab are also provided. In some embodiments, a dosage pack comprises instructions for administering FGFR1 ECD and/or FGFR1 ECD fusion molecule with at least one additional therapeutic agent.

